Holen Sie sich die Stockscreener-App
8.761
1.81%
0.161
Schlusskurs vom Vortag:
$8.60
Offen:
$8.68
24-Stunden-Volumen:
110.42K
Relative Volume:
0.39
Marktkapitalisierung:
$586.71M
Einnahmen:
$555.06M
Nettoeinkommen (Verlust:
$-39.48M
KGV:
-14.60
EPS:
-0.6
Netto-Cashflow:
$29.05M
1W Leistung:
+4.11%
1M Leistung:
+5.88%
6M Leistung:
+21.11%
1J Leistung:
-8.89%
1-Tages-Spanne:
$8.555
$8.79
1-Wochen-Bereich:
$8.11
$8.99
52-Wochen-Spanne:
$5.81
$10.13
Bioventus Inc Stock (BVS) Company Profile
Firmenname
Bioventus Inc
Sektor
Branche
Telefon
(919) 474-6700
Adresse
4721 EMPEROR BOULEVARD, SUITE 100, DURHAM
Compare BVS vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BVS
Bioventus Inc
|
8.76 | 576.00M | 555.06M | -39.48M | 29.05M | -0.60 |
|
ABT
Abbott Laboratories
|
108.68 | 187.91B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
339.50 | 129.05B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
87.47 | 112.19B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
68.97 | 101.72B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
81.63 | 49.14B | 6.07B | 1.06B | 1.34B | 1.8063 |
Bioventus Inc Stock (BVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-09 | Eingeleitet | Barrington Research | Outperform |
| 2025-07-07 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-17 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-12-07 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-08-09 | Hochstufung | Craig Hallum | Hold → Buy |
| 2022-11-22 | Herabstufung | Craig Hallum | Buy → Hold |
| 2022-11-09 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-11-09 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2022-03-15 | Eingeleitet | Craig Hallum | Buy |
| 2021-11-15 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-11-10 | Fortgesetzt | JP Morgan | Overweight |
| 2021-07-01 | Herabstufung | Goldman | Buy → Neutral |
| 2021-03-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-03-08 | Eingeleitet | Goldman | Buy |
| 2021-03-08 | Eingeleitet | JP Morgan | Overweight |
| 2021-03-08 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Bioventus Inc Aktie (BVS) Neueste Nachrichten
Bioventus Inc. (NASDAQ:BVS) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Bioventus stock delivers 63% return after Fair Value signal - Investing.com
Liquidity Mapping Around (BVS) Price Events - Stock Traders Daily
Orthobiologics Market to Surpass USD 9 Billion by 2031 Amid Rising Osteoarthritis Cases and Advancements in Regenerative Therapies, Says Mordor Intelligence - GlobeNewswire Inc.
Earnings call transcript: Bioventus Inc. Q4 2025 beats EPS estimates, stock surges - Investing.com Nigeria
Bioventus Earnings Call Signals Profitable Growth Ahead - TipRanks
Bioventus Inc. (NASDAQ:BVS) Q4 2025 earnings call transcript - MSN
Momentum Shift: How is Bioventus Inc managing supply chain issues2026 Breakouts & Breakdowns & Stepwise Trade Signal Implementation - baoquankhu1.vn
Risks Report: Is Bioventus Inc exposed to currency risksJuly 2025 Chart Watch & Growth Focused Stock Pick Reports - baoquankhu1.vn
Craig-Hallum Maintains Buy on Bioventus Inc (BVS) March 2026, PT $16 - Meyka
Aug Action: Will Bioventus Inc benefit from rising consumer demandProduct Launch & Technical Pattern Alert System - baoquankhu1.vn
Bioventus (NYSE:BVS) In Focus as NYSE Composite Tracks MedTech Moves - Kalkine Media
Bioventus (BVS) Receives Updated Price Target from Barrington Re - GuruFocus
Bioventus (NYSE:BVS) Stock Price Expected to Rise, Barrington Research Analyst Says - MarketBeat
Bioventus (NASDAQ:BVS) Shares Down 8.2%Here's Why - MarketBeat
Bioventus (NYSE:BVS) Given New $16.00 Price Target at Craig Hallum - MarketBeat
Craig-Hallum raises Bioventus stock price target on guidance beat By Investing.com - Investing.com India
Craig-Hallum raises Bioventus stock price target on guidance beat - Investing.com South Africa
Bioventus Inc. (NASDAQ:BVS) Q4 2025 Earnings Call Transcript - Insider Monkey
Bioventus: Q4 Earnings Snapshot - theheraldreview.com
Bioventus earnings beat by $0.04, revenue topped estimates - Investing.com Australia
BVS Targets Revenue Range of $600M-$610M for FY26 - GuruFocus
Bioventus Q4 Earnings Call Highlights - MarketBeat
Bioventus Inc (BVS) Q4 2025 Earnings Call Highlights: Strong Org - GuruFocus
Bioventus (NYSE:BVS) Shares Gap UpHere's Why - MarketBeat
Bioventus Shares Rise After Analyst Upgrade - National Today
Bioventus Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Bioventus (NASDAQ:BVS) Shares Gap Up After Analyst Upgrade - MarketBeat
Bioventus (BVS) Q4 2025 Earnings Call Transcript - AOL.com
Earnings call transcript: Bioventus Inc. Q4 2025 beats EPS estimates, stock surges By Investing.com - Investing.com South Africa
Bioventus (NASDAQ:BVS) Rating Increased to Strong-Buy at Cantor Fitzgerald - MarketBeat
Bioventus shares jump 7.6% on fourth-quarter earnings beat By Investing.com - Investing.com Canada
Bioventus shares jump 7.6% on fourth-quarter earnings beat - Investing.com Australia
Bioventus beats Q4 estimates, guides 2026 revenue in line By Investing.com - Investing.com Australia
Bioventus Q4 2025 Earnings Call Transcript - MarketBeat
Bioventus 10-K: $568.1M Revenue, $0.33 Diluted EPS - TradingView
Bioventus (BVS) Exceeds Q4 Revenue Expectations, Eyes Future Gro - GuruFocus
Bioventus Q4 and Full Year 2025 Financial Results - TradingView
BIOVENTUS ($BVS) Releases Q4 2025 Earnings - Quiver Quantitative
Bioventus beats Q4 estimates, guides 2026 revenue in line - Investing.com India
Bioventus (NYSE:BVS) Updates FY 2026 Earnings Guidance - MarketBeat
Bioventus Announces Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Bioventus Q4 Earnings Assessment - Benzinga
Bioventus beats Q4 revenue estimates on strong demand for pain treatments and surgical solutions - TradingView
Bioventus Earnings Report: Q4 Overview - Benzinga
BVS SEC FilingsBioventus Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Technical Analysis: Will Bioventus Inc benefit from rising consumer demandProduct Launch & Daily Oversold Bounce Ideas - baoquankhu1.vn
Preview: Bioventus's Earnings - Benzinga
Bioventus Inc. $BVS Shares Bought by Royce & Associates LP - MarketBeat
Bioventus (BVS) versus Its Peers Critical Comparison - Defense World
Bioventus (NYSE:BVS) Stock Price Down 0.1%Should You Sell? - MarketBeat
Finanzdaten der Bioventus Inc-Aktie (BVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.42%
0.75%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):